Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?

References

• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM: Relapse prevention in schizophrenia with new generation antipsy-chotics: A systematic review and exploratory meta-analysis of ran-domized, controlled trials. Am J Psychiatry 2003; 160:1209–1222
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6):553–564
   PubMed Web of Science ®Google Scholar
• Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binord R, Gunatilake S: Atypical antipsychotic induced weight gain: Patho-physiology and management. Ann Clin Psychiatry 2004; 16(2):75–85
   PubMedGoogle Scholar
• Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Res 2004; 70:1–17
   PubMed Web of Science ®Google Scholar
• Schweinkreis P. Assion HJ: Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004; 5:73–82
   Google Scholar
• Melkerson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical impli-cations. Drugs 2004; 64:701–723
   PubMedGoogle Scholar
• Lehman AF, Lieberman JA: Work group on schizophrenia: Prac-tice Guideline for the Treatment of Patiens with Schizophrenia. Second Edition. APA, 2004; 3–5
   Google Scholar
• Serrerti A, De Ronchi D, Lorenzi C, Bernardi D. New antipsy-chotics and schizophrenia: A review on efficacy and side effects. Curr Med Chem 2004; 11:343–358
   Google Scholar
• Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765–774
   PubMed Web of Science ®Google Scholar
• Van Bruggen J, Tijssen J, Dingemans P. Gersons B, Linszen D: Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psy-chopharmacology 2003; 18:341–346
   Google Scholar
• Martin S, Loo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot 0, Rein W, SOLIANOL Study Group: A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treat-ment of schizophrenia: Short-term results at two months. Curr Med Res Opin 2002; 18(6):355–362
   PubMed Web of Science ®Google Scholar
• Mortimer A, Martin S, Loo H, Peuskens J, SOLIANOL Sudy Group: A double-blind, randomized comparative trial of amisul-pride versus olanzapine for 6 months in the treatment of schizo-phrenia. Int Clin Psychopharmacol 2004; 19:63–69.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Bech P. Moller HJ: Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88:107–117
   Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsy-chotic with a novel mechanism of action, and risperidone vs. pla-cebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681–690
   PubMed Web of Science ®Google Scholar
• Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO: Ran-domized, controlled, double-blind multicenter comparison or the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:1837–1847
   PubMed Web of Science ®Google Scholar
• Harvey PD, Siu CO, Romano S: Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004; 172:324–332
   PubMed Web of Science ®Google Scholar
• Addington DEN, Pantelis CH, Dineen M, Benattia I, Romano SJ: Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004; 65:1624–1633
   Google Scholar
• Ho BC, Miller D, Nopoulos P, Andreasen NC: A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60:658–663
   Google Scholar
• Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M: Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001; 1:7. Epub 2001 Dec 28.
   Google Scholar
• Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O–Halloran RA, Bitter I, ICSOHO Study Group: IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004; 65: 312–321
   Google Scholar
• Dinakar HS, Sobel RN, Bopp JH, Daniels A, Mauro S: Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. Psychiatr Serv 2002; 53:755–757
   Google Scholar
• Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Ryzno S, Weizman R, Ratzoni G: Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003; 110:545–560
   Google Scholar
• Mullen J, Jibson MD, Sweitzer D: A comparison of the relative safety, efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics 2001; 23:1839–1854
   Google Scholar
• Briken P, Nika E, Moritz S Haasen C, Perro C, Yagdiran O, Naber D, Krausz M: Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophr Res 2002; 57:311–313
   Google Scholar
• Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155:499–504
   Google Scholar
• Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clinton A, Picka D: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects and neuroendocrine response. Am J Psychiatry 1999; 156:294–298
   Google Scholar
• Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R: Risperidone versus clozapine in treatment resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol and Biol Psychiatr 2000; 24:911–922
   Google Scholar
• Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I: A double blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001; 158:1305–1313
   Google Scholar
• Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49:52–63
   Google Scholar
• Bitter I, Dossenbach MRK, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Fredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A, Olanzapine HGCK Study Group: Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Bioll Psychiatry 2004; 28:173–180
   Google Scholar
• Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chaos M, Lieberman JA: Effects of clozapine, olanzapine, risperidone and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52:1510–1514
   Google Scholar
• Bilder RM, Goldman RS, Volavka J, Ctibor P, Hoptman N, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chaos M, Cooper TB, Horowitz TL, Lieberman JA: Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018–1028
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407–418
   Google Scholar
• Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A: Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18:567–579
   Google Scholar
• Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A: Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry 2003; 64:998–1004
   Google Scholar
• Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM: Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003; 61:303–314
   Google Scholar
• Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000; 57:249–258
   Google Scholar
• Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulpride Study Group: Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002; 27: 1071–1081
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353:1209–1223. Epub 2005 Sep 19
   Google Scholar
• Soholm B, Lublin H: Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand 2003; 107:344–350
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, Ernst FR: A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004; 3:11
   PubMedGoogle Scholar
• Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Arch Gen Psychiatry 2003; 60:82–91
   Google Scholar
• Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: A critical overview. CMAJ 2005; 172:1703–1711
   Google Scholar